Skip to main content
. Author manuscript; available in PMC: 2019 May 21.
Published in final edited form as: Exp Physiol. 2019 Mar 14;104(5):654–666. doi: 10.1113/EP087304

Figure 4. Surface and t-tubular ICa.

Figure 4.

(A) Top panel: Exemplar records of ICa from intact sham (black) and TAC (grey) Cav-3 OE myocytes. Bottom panel: corresponding mean ICa density-voltage relationships from sham (n/N=19/5) and TAC (n/N=22/5) Cav-3 OE myocytes (Two-way repeated measures ANOVA: mV p< 0.001, TAC p=0.4, interaction p< 0.9). (B) Top panel: Exemplar records of ICa from detubulated (DT) sham (black) and TAC (grey) Cav-3 OE myocytes. Bottom panel: corresponding mean ICa density-voltage relationships from DT sham (n/N=19/5) and TAC (n/N=21/5) Cav-3 OE myocytes. (Two-way repeated measures ANOVA: mV p< 0.001, TAC p< 0.001, interaction p< 0.001). (C) absolute ICa and (D) ICa density at 0 mV in intact Cav-3 OE myocytes, and at the cell surface and t-tubules (obtained as described in Methods), compared with previously published data (Bryant et al., 2018a) from WT mice. ** p<0.01, *** p<0.001 between treatments for a given phenotype (WT or Cav-3 OE); # p<0.05, ## p<0.01, ### P<0.001 between phenotypes for a given treatment (sham or TAC). (E) mean ICa density-voltage relationships from sham untreated (n/N=19/5) and C3SD treated (n/N=12/3) Cav-3 OE myocytes. (Two-way repeated measures ANOVA: mV p< 0.001, C3SD p=0.014, interaction p< 0.001). (F) mean ICa density-voltage relationships from TAC untreated (n/N=22/5) and C3SD treated (n/N=17/5) myocytes (Two-way repeated measures ANOVA: mV p< 0.001, C3SD p=0.13, interaction p= 0.4). (G) mean ICa density at 0 mV in sham untreated and C3SD treated Cav-3 OE myocytes, compared with previously published data (Bryant et al., 2018a; see Methods) from sham untreated (n/N=16/5) and C3SD treated (n/N=17/5) WT myocytes, (Two-way ANOVA: OE p< 0.001, C3SD p=0.4, interaction p< 0.001). (H) mean ICa density at 0 mV in TAC untreated and C3SD treated Cav-3 OE myocytes, compared with previously published data (Bryant et al., 2018a; see Methods) from TAC untreated (n/N=19/5) and C3SD treated (n/N=15/5) WT myocytes (Two-way ANOVA: OE p< 0.001, C3SD p=0.14, interaction p=0.84). * p<0.05, ** p<0.01 between treatments for a given phenotype (WT or Cav-3 OE); ### P<0.001 between phenotypes for a given treatment.